Dopa-decarboxylase inhibitor + dopamine precursor. ≥18yrs: Do not crush or chew. Patients not receiving levodopa: initially one Sinemet CR 50–200 tab twice daily, at intervals of at least 6 hrs.
Designed for advanced Parkinson’s with poorly controlled motor fluctuations, the infusion delivers steadier levodopa exposure than pills via continuous subcutaneous dosing.
Parkinson’s disease is a progressive neurodegenerative disorder that affects millions of people worldwide. In the United States, it is estimated that almost one million people have Parkinson’s.
The cardinal motor features of PD are bradykinesia, rigidity and resting tremor. The disease is typically asymmetric, starting on one side and remaining worse on that side as the disease progresses.
VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease Adults treated with VYALEV ...
The FDA approved a subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopa (Vyalev) for advanced Parkinson's disease, AbbVie announced Thursday. Foscarbidopa and foslevodopa are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results